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Abstract
Organophosphorus nerve agents (OPNAs) are toxic compounds that are classified as prohibited 
Schedule 1 chemical weapons. In the body, OPNAs bind to butyrylcholinesterase (BChE) to form 
nerve agent adducts (OPNA-BChE). OPNA-BChE adducts can provide a reliable, long-term 
protein biomarker for assessing human exposure. A major challenge facing OPNA-BChE 
detection is hydrolysis (aging), which can continue to occur after a clinical specimen has been 
collected. During aging, the o-alkyl phosphoester bond hydrolyzes, and the specific identity of the 
nerve agent is lost. To better identify OPNA exposure events, a high throughput method for the 
detection of five aged OPNA-BChE adducts was developed. This is the first diagnostic panel to 
allow for the simultaneous quantification of any Chemical Weapons Convention Schedule 1 OPNA 
by measuring the aged adducts methyl phosphonate (MeP-BChE), ethyl phosphonate (EtP-BChE), 
propyl phosphonate (PrP-BChE), ethyl phosphoryl (ExP-BChE), phosphoryl (P-BChE), and 
unadducted BChE. The calibration range for all analytes is 2.00 – 250. ng/mL, which is consistent 
with similar methodologies used to detect unaged OPNA-BChE adducts. Each analytical run is 
three minutes making the time to first unknown results, including calibration curve and quality 
controls, less than one hour. Analysis of commercially purchased individual serum samples 
demonstrated no potential interferences with detection of aged OPNA-BChE adducts, and 
quantitative measurements of endogenous levels of BChE were similar to those previously 
reported in other OPNA-BChE adduct assays.
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1. Introduction
Organophosphorus nerve agents (OPNAs) are compounds that are classified by the 
Chemical Weapons Convention (CWC) as prohibited Schedule 1 chemical weapons.(OPCW, 
2005) There have been several documented OPNA uses, including the Iraq-Iran conflict in 
1984, Japan in 1994 and 1995, and Syria in 2013.(Pita and Domingo, 2014, Suzuki et al., 
1995, UN, 1984, Yanagisawa et al., 1995) OPNAs are toxic chemicals that induce nausea, 
vomiting, convulsions, seizures, and death by binding to the active site serine of the 
cholinesterase enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).
(Grob and Harvey, 1953, Schecter, 2004) The toxicity of OPNAs, as well as their relative 
ease of synthesis, make them a concern for use as a weapon.(Evison et al., 2002) In addition 
to intentional exposure, there is also an increased risk for accidental exposure during the 
destruction of legacy stockpiles. This is especially of concern given the current efforts by the 
Organisation for the Prohibition of Chemical Weapons (OPCW) to eradicate OPNA 
stockpiles by 2023.(OPCW, 2015)
In the body, OPNAs can undergo hydrolysis, making direct measurement of the live agent of 
exposure difficult.(Black, 2010) Nerve agent metabolites can be detected in blood and urine; 
however, these metabolites are excreted from the body within two weeks following 
exposure.(Hamelin et al., 2014, Mawhinney et al., 2007, Riches et al., 2005) OPNAs also 
form protein adducts which can provide a previously reported two to three months for 
retrospective detection.(Black and Read, 2013) The Ellman activity assay has been used to 
determine OPNA exposure by measuring cholinesterase activity but lacks the specificity to 
distinguish OPNAs from organophosphorus pesticides or other compounds capable of 
inhibiting cholinesterases.(Ellman et al., 1961) Fluoride reactivation provides a sensitive 
method for detecting OPNA exposure, but agents that have undergone hydrolysis (aging) 
cannot be reactivated; therefore, rapidly aging OPNAs such as soman (GD) may not be 
detected.(Adams et al., 2004, Heilbronn, 1965, Heilbronn, 1965) Direct measurement of 
OPNA-adducted proteins has become an increasingly utilized method for retrospective 
detection.(Crow et al., 2014, Noort et al., 2006, Van der Schans et al., 2008, Williams et al., 
2007) OPNAs readily react with BChE which provides a reliable biomarker for measuring 
OPNA exposure. OPNA-BChE adducts have relatively long half-lives (8–12 days), are 
abundant in serum and plasma, and can easily be extracted from blood since BChE is not 
membrane-bound.(Knaack et al., 2012, Pantazides et al., 2014, Sporty et al., 2010)
A major challenge facing direct measurement of OPNA-BChE adducts is an aging process 
caused by hydrolysis. The o-alkyl phosphoester bond of OPNA-BChE adducts ages over 
time in biological matrices, and the specific identity of the agent is lost (Figure 1).(Carter et 
al., 2013, Segall et al., 1993) For example, sarin (GB), cyclosarin (GF), GD, VX, VM, and 
VR all share a common methyl-phosphorus bond that is preserved after reaction with the 
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active site serine of BChE, giving rise to the aged methyl phosphonate biomarker, MeP-
BChE.(Berry and Davies, 1966, Segall et al., 1993) Although the specific identity of the 
OPNA cannot be determined following aging, identification of MeP-BChE is indicative of 
organophosphorus exposure. Similarly, ethyl sarin (GE) and VE (O-ethyl-S-
diethylaminoethylphosonothiolate) share a common ethyl-phosphorus bond, giving rise to 
the aged ethyl phosphonate biomarker, EtP-BChE. Only synthetic analogues of the methyl 
and ethyl OPNAs, such as propyl-sarin (Pr-GB), would be expected to form the propyl 
phosphonate biomarker, PrP-BChE. The methyl, ethyl, and propyl phosphonate adducts are 
unique to OPNAs and are not known to be formed by any organophosphorus pesticides.
(Jiang et al., 2013) A phosphoryl adduct (P-BChE) can be formed by OPNAs such as tabun 
(GA) and GV (2-dialkylaminoalkyl N,N-dialkylphosphonamidofluoridate), but can also be 
generated from the industrial additive cresyl saligenin phosphate (CBDP).(Carletti et al., 
2008, Liyasova et al., 2011) In the case of GA, aging through deamidation has also been 
reported, producing an ethyl phosphoryl adduct (ExP-BChE).(Barak et al., 2000, Elhanany 
et al., 2001) However, this additional adduct (+108 Da) is not specific to GA. 
Organophosphorus pesticides containing a diethoxyphosphate group can also undergo aging 
to produce ExP-BChE.(Jiang et al., 2013, Jiang et al., 2013)
The formation of aged OPNA-BChE adducts can continue to occur after a clinical specimen 
has been collected, highlighting the need for a method to quantify aged biomarkers.(Berry 
and Davies, 1966) Previous reports have described methods that could be used to detect aged 
biomarkers of OPNA exposure; however, these assays required additional sample analysis to 
identify or confirm the agent of exposure.(Noort et al., 2006, Van der Schans et al., 2008) To 
better identify OPNA exposure events, a high-throughput method for the detection and 
quantitation of aged OPNA-BChE adducts has been developed. The method described herein 
provides simultaneous quantification of P-BChE, MeP-BChE, ExP-BChE, EtP-BChE, PrP-
BChE, and unadducted BChE biomarker peptides in human blood matrices. Monitoring this 
panel of aged OPNA-BChE biomarkers allows for the detection of all CWC Schedule 1 
OPNAs.
2. Materials and methods
2.1 Materials
The following materials were purchased from Sigma Aldrich (St. Louis, MO, USA): 
phosphate buffered saline with Tween 20 (PBST) dry powder, dimethyl pimelimidate 
dihydrochloride, 0.2 M tris buffered saline (TBS) 10X concentrate, triethanolamine buffer 
solution, and pepsin from porcine gastric mucosa. The following items were purchased from 
Fisher Scientific (Hanover Park, IL, USA): Optima LC/MS grade formic acid, KingFisher 
shallow well plates (PN: 22-387-030), KingFisher 96 tip combs (PN: 22-387-029), 
KingFisher deep well plates (PN: 12-565-651), Fisherbrand deep well plates (PN: 
12-566-121), Pierce protein precipitation plates, and Eppendorf PCR adhesive foil. 
Eppendorf heat-sealing foil was purchased from VWR (Radnor, PA, USA). High-
performance liquid chromatography (HPLC)-grade acetonitrile and deionized water were 
commercially available from Tedia (Fairfield, OH, USA). Ultrapure 18.2 MΩ-cm water was 
generated in-house with an Aqua Solutions Water Purification system (Jasper, GA, USA). 
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Dynabeads Protein G magnetic beads were obtained from Life Technologies (Carlsbad, CA, 
USA). BChE monoclonal antibodies from clone 3E8 were purchased from BioPorto 
(Hellerup, Denmark).
The Netherlands Organisation for Applied Scientific Research (TNO; Rijswijk, Netherlands) 
provided synthetic native and isotopically-labeled BChE and P-BChE peptides. Battelle 
Memorial Institute (Columbus, OH, USA) provided synthetic native and isotopically-labeled 
MeP-BChE, ExP-BChE, EtP-BChE, and PrP-BChE peptides. For PrP-BChE, two isoforms 
are possible, i-PrP-BChE and n-PrP-BChE. These isoforms have the same mass, but could 
not be separated chromatographically. Therefore, this work only uses i-PrP-BChE synthetic 
standards, but the method would be able to detect either isoform. Commercial pooled serum 
was purchased from Bioreclamation, Inc. (Westbury, NY, USA) and TNO. Cresyl saligenin 
phosphate (CBDP) inhibited serum (98% BChE inhibition) was procured from TNO. GE 
(99.4% BChE inhibition), GV (99.3% BChE inhibition) and Propyl GB (98.8% BChE 
inhibition) inhibited serum were purchased from Battelle. Sarin-inhibited serum and plasma 
(98% inhibition) were obtained from Battelle Memorial Institute and the U.S. Army 
Edgewood Chemical Biological Center. A commercial convenience set consisting of serum 
from 96 healthy individuals with no expected OPNA exposure was purchased from 
Tennessee Blood Services (Memphis, TN, USA). The method used blood products acquired 
from commercial sources, and the work did not meet the definition of human subjects as 
specified in 45 CFR 46.102 (f). The commercial blood products were screened for the 
presence of pathogens prior to commercial sale.
2.2 Preparation of calibrators and quality controls
Amino acid analysis of synthetic peptides was carried out by New England Peptide 
(Gardner, MA, USA) prior to preparation of calibration and quality control solutions. Stock 
solutions were made for each native and isotopically-labeled standard at 1.00 mg/mL in 
ultrapure water. Native peptide stock solutions were combined and diluted in ultrapure water 
at concentrations of 2.00, 4.00, 8.00, 16.0, 32.0, 63.0, 125, and 250. ng/mL. A single internal 
standard (ISTD) solution was prepared that consisted of isotopically-labeled peptides P-
[13C9]-BChE (450 ng/mL), MeP-[13C9,15N]-BChE (250 ng/mL), ExP-[13C9]-BChE 
(250.ng/mL), EtP-[13C9,15N]-BChE (250 ng/mL), [13C9]-BChE (250 ng/mL), and PrP-
[13C9,15N]-BChE (100 ng/mL) peptides. The structures of the isotopically-labeled peptides 
with sites of labeling can be found in Figure 2. 10 kDa MWCO filtered uninhibited human 
serum was used as matrix blank. The filtration was found to remove endogenous BChE from 
the serum, and therefore did not interfere with the detection of BChE calibrators.
Five quality control (QC) samples were prepared: high level QC (QH), mid-level BChE QC 
(QM-BChE), mid-level QC (QM), low level P-BChE QC (QL-P-BChE), and low level QC 
(QL). QL, QM, and QH were prepared by spiking synthetic peptides into 10 kDa filtered 
uninhibited serum at 10.0, 40.0, and 80.0 ng/mL. Pooled commercial uninhibited serum 
from TNO was used as QM-BChE. A 2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one 
(cresyl saligenin phosphate or CBDP) inhibited serum from TNO, which is known to 
hydrolyze to form the P-BChE adduct, was used as QL-P-BChE.(Schopfer et al., 2010) 
Uninhibited pooled human serum (QM-BChE) and pooled serum fully inhibited with oCP 
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(QL-P-BChE) were included in the QC characterization material to verify digestion by 
pepsin. Since these are serum-based QC materials, it ensures proper sample preparation for 
unknown samples. QC material characterization was completed over the course of 4 weeks 
during method validation (n = 24) and performed by five laboratory analysts following the 
CDC’s multi-rule quality control system (MRQCS). (Caudill et al., 2008)
2.3 Sample preparation
Samples were prepared as previously described with additional optimization.(Johnson et al., 
2015, Knaack et al., 2012, Pantazides et al., 2014) Briefly, a DynaMag-15 (Invitrogen, 
Carlsbad, CA) was applied to remove the solvent from 2 mL of Dynabeads Protein G 
magnetic beads. The beads were washed twice with 4 mL aliquots of PBST, and then 8 mL 
of PBST was added to the beads followed by 400 μg of anti-BChE monoclonal antibody. 
This mixture was allowed to rotate on a Dynal Sample mixer at speed setting 20 for one hour 
at room temperature; after which, the solvent was removed, and the beads were washed 
twice with 4 mL aliquots of triethanolamine buffer. A 4 mL aliquot of a 5.4 mg/mL solution 
of dimethyl pimelimidate dihydrochloride in triethanolamine buffer was added to the 
magnetic beads, and this was allowed to rotate for 30 minutes at speed setting 20 at room 
temperature. After the solvent was removed, 4 mL of TBS was added, and then the magnetic 
beads were allowed to rotate for 15 min at speed setting 20 at room temperature. The solvent 
was removed after rotation, and the magnetic beads were washed twice with 2 mL aliquots 
of PBST. Finally, 1.9 mL of PBST was added to the beads, and they were stored at 4 °C for 
use up to 3 months.
After antibody conjugated bead preparation, 125 μL aliquots of either serum or plasma were 
pipetted into a multiscreen HTS HV 0.45 μm opaque filter plate and then centrifuged for 5 
minutes at 3000 × g and 20 °C. A 75 μL aliquot of the filtered serum or plasma was 
transferred into a KingFisher deep 96-well plate. A 50 μL aliquot of anti-BChE magnetic 
beads were added to the wells of a KingFisher shallow plate that corresponded to wells that 
contained serum or plasma. A KingFisher Flex magnetic particle processor (Thermo 
Scientific, Waltham, MA, USA), was used to transfer the anti-BChE beads to the sample 
plate containing the serum or plasma. The sample plate was then covered with adhesive foil, 
and allowed to shake for 45 min on an Eppendorf MixMate (Eppendorf, Hamburg, 
Germany) at 1400 rpm at room temperature. The KingFisher Flex was used to transfer the 
BChE bound magnetic beads to three deep well wash plates containing 500 μL PBST, and 
finally to a KingFisher shallow 96-well plate for digestion. The digestion plate contained 10 
μL of 2 mg/mL pepsin in 0.6% formic acid in ultrapure water and 10 μL of the isotopically-
labeled internal standard in each well. In wells that were used for calibration or that 
contained a synthetic peptide QC spike, 75 μL of the appropriate solution was added, and to 
the remaining wells, 75 μL of 0.6% formic acid in ultrapure water was added. The digestion 
plate was covered with adhesive foil and placed in an Eppendorf Thermomixer R (Hamburg, 
Germany) for 30 min at 37 °C with intermittent shaking at 1000 rpm for 10 sec every min. 
After digestion, the anti-BChE beads were removed from the digestion plate using the 
KingFisher Flex. A 285 μL aliquot of acetonitrile was added to each well of the protein 
precipitation plate used and followed by the addition of the digested samples. This plate was 
allowed to shake for 1 min at 1,000 rpm before being filtered through the protein 
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precipitation plate using a vacuum manifold, and a deep 96-well plate as a receiving plate. 
The samples were dried to completeness using a Porvair Ultravap (Porvair Sciences, 
Wrexham, UK) at 60 °C under a nitrogen stream. Samples were resuspended in 75 μL of 
0.6% formic acid in ultrapure water for UHPLC-MS/MS analysis. A flowchart summarizing 
the sample preparation procedure has been included Scheme 1 for clarity.
2.4 UHPLC-MS/MS
The BChE biomarker peptides were evaluated using an Agilent 1290 Infinity series UHPLC 
system (Santa Clara, CA, USA) coupled with an Agilent 6490 triple quadrupole mass 
spectrometer with a jet stream ionization source, operating in positive ionization mode. The 
instrument was tuned and calibrated bimonthly using the Agilent ESI tuning mixture (P/N 
G1969) over a range of 50–1400 m/z. Chromatographic separation was carried out on a 
Restek Pinnacle DB Biphenyl 1.9 μm, 2.1 × 50 mm analytical column (Bellefonte, PA, 
USA). The column compartment and autosampler temperatures were set to 60 °C and 10 °C, 
respectively. Mobile phases consisted of 0.1% formic acid in (A) water and (B) acetonitrile, 
delivered at a flow rate of 300 μL/min. Gradient conditions increased mobile phase B 
concentration from 5% to 23% over 1.55 min, from 23% to 76% over 0.28 min, held 76% 
for 0.17 min followed by a re-equilibration step at 5% mobile phase B for 1.0 min. A total 
analysis time of 3 min per sample was achieved. The following parameters were used with 
the jet stream ionization source: drying gas temperature = 220 °C; drying gas flow = 11 L/
min; nebulizer = 60 psi; sheath gas temperature = 350 °C; sheath gas flow = 11 L/min; 
capillary voltage = 3500 V; nozzle voltage = 1800 V; iFunnel high pressure RF = 190 V; 
iFunnel low pressure RF = 120 V; fragmenter voltage = 250 V. The mass spectrometer was 
operated in multiple reaction monitoring mode, with the two most selective transitions for 
the native BChE biomarker peptides being monitored for quantitation and confirmation. A 
single transition was monitored for each of the isotopically-labeled biomarker peptides. P-
BChE and MeP-BChE transitions were acquired in time-segment 1 (0.00–1.54 min) with a 
35 ms dwell time. ExP-BChE and EtP-BChE transitions were acquired in time-segment 2 
(1.54–1.65 min) with a 20 ms dwell time. BChE and PrP-BChE transitions were acquired in 
time-segment 3 (1.65–1.90 min) with a 35 ms dwell time. See Table 1 for parameters for 
peptide detection.
2.5 Recovery and Matrix Effects
Since an isotopically-labeled BChE protein is not currently available, recovery of aged 
OPNA-BChE and unadducted BChE peptides was determined by adding calibrators at low 
(2.00 ng/mL), mid (32.0 ng/mL), and high (250 ng/mL) level spikes to the matrix blank 
serum prior to pepsin digestion (“processed”) or immediately following pepsin digestion 
(“unprocessed”). Recovery was assessed by comparing the average chromatographic peak 
area (n = 4) of the processed calibrators to the unprocessed calibrators. Matrix effects were 
evaluated by comparing the average peak area (n = 4) of unprocessed calibrators in matrix 
blank serum to calibrators spiked into 0.6% formic acid in water at low, mid, and high level 
spikes.
Graham et al. Page 6
Biomed Chromatogr. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.6 Stability and Ruggedness
In order to determine the stability of assay materials, the calibrators and QCs were subjected 
to cycles of freeze/thaw and various storage temperature conditions. The effects of calibrator 
and QC storage temperatures were examined after 8 freeze-thaw cycles, each from −70 °C to 
room temperature. The stability of the calibrators and QM-BChE material was evaluated by 
storing the materials at 4 °C, room temperature, or 37 °C, and evaluating them after 4, 8, 24, 
48, and 72 hours. Analysis of QM-BChE material was extended, also collecting data after 5 
and 7 days. Evaluation was based on calculated concentrations, and storage conditions were 
determined acceptable if calculated concentrations were within ±2 standard deviations of 
their characterized means (Tables 2 and 3, n=24). The ruggedness of the method was 
evaluated on five parameters that represent steps in the UHPLC-MS/MS analysis that might 
be impacted by changes to the validated assay. The resuspension buffer (0.1% formic acid 
and 0.6% formic acid), UHPLC organic mobile phase (acetonitrile and methanol), LC 
column lot (8 different products lots), LC gradient slope (linear and increased slope), and LC 
flow rate (± 100 μL/min) were varied individually, and the effect of each was evaluated 
using QC samples. Evaluation was based on the calculated QC concentrations, and altered 
parameters were determined to have an impact on the assay if the QC concentrations were 
outside of ±2 standard deviations of their characterized means (Table 3).
2.7 Matrix Blank and Convenience Set Analysis
Previous methods developed for the quantification of OPNA adducts to BChE have used 
GB- or GA-inhibited serum as the matrix blank. These inhibited materials would interfere 
with the measurement of aged biomarkers because GB- and GA-BChE undergo aging to 
MeP-BChE, P-BChE, or ExP-BChE. Each of these materials, unaged GB-inhibited serum, 
unaged GA-inhibited serum, and filtered serum were used to prepare calibration curves 
following the sample preparation protocol described in section 2.3. A comparison of the 
slopes of the calibration curves in GB-inhibited, GA-inhibited and 10 kDa filtered serum 
was carried out to determine if the 10 kDa filtered serum would be within 5% and therefore 
an acceptable matrix blank. The validated method was also applied to analyze a convenience 
set of 96 commercially-obtained individual human serum samples to assess background and 
possible interferences in an unexposed population.
2.8 Evaluation of Nerve Agent Spiked Materials
To demonstrate the utility of this assay, human serum spiked with GE, GV, and propyl GB 
(Pr-GB) were incubated at 37 °C for at least one week and analyzed (n = 5) using the 
validated method. Each of the agents in Figure 3 are expected to undergo hydrolysis to form 
aged products. GE and VE (Figures 5A and 5D) are expected to form EtP-BChE, while GV 
(Figure 3B) would form P-BChE, and Pr-GB (Figure 3C) would form PrP-BChE. For 
thermal stability studies, sarin (GB) inhibited serum and plasma were analyzed prior to and 
during aging of GB-BChE. Individual aliquots of inhibited serum and plasma were 
incubated ex vivo at 4 °C, 22 °C (benchtop) and 37 °C over the course of one month. 
Approximately 15 time points (n=1) were collected for each temperature and stored at 
−70 °C until analysis in the panel. Upon analysis, the concentration of each biomarker was 
determined and plotted against time (ln[C] = −kobst + ln[C]0). First order conditions were 
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assumed from previous literature and applied to the GB-BChE decay in order to calculate 
the resulting rate constant (k) and half-life (t1/2) using . First order conditions were 
applied again when calculating the rate constant of MeP-BChE and unadducted BChE 
formation. Likewise, first order conditions were used to calculate the rate constant of the 
regeneration of BChE activity. The activation energy of decay was calculated by 
, where T1 = 310 K and T2 = 295 K, and R is the ideal gas 
constant (1.987 cal·K-1·mol-1). The pre-exponential factor, A, was calculated using 
.
Finally, the untargeted analysis used to look for potential new BChE biomarkers from the 
observed GB-BChE decay was processed the same as the diagnostic BChE biomarkers and 
analyzed by UHPLC-HRMS/MS. Discrimination of potential decay product biomarkers was 
completed using ddMS2 scan filtering for the signature [M+H]+ BChE peptide fragments 
m/z 673.2940, 602.2569 and 778.3366 within 10 ppm error at 70,000 resolution. HRMS/MS 
experiments were carried out on a Thermo Q-Exactive Hybrid Quadrupole Orbitrap Mass 
Spectrometer.
2.9 Data Acquisition and Processing
MassHunter Workstation Software, LC/MS Data Acquisition for 6400 Series Triple 
Quadrupole v. B.06.00, Build 6.0.6025.3 SP3 was used for data acquisition. MassHunter 
Workstation Software Quantitative Analysis v. B.06.00 SP01, build 6.0.388.1 was used for 
spectral analysis and quantitation. Accuracy was reported in percent relative error, % RE = 
[Ce−Ct]/Ct × 100, where Ce and Ct are the experimental concentration determined from the 
calibration curve and the theoretical concentration, respectively. The percent relative 
standard deviation, % RSD = SD/Cavg × 100, was calculated as a measure of assay 
precision, where Cavg and SD are the average calculated concentration and the standard 
deviation, respectively.
Calibration curves were created for each analyte in matrix blank serum by plotting the area 
of the analyte divided by the area of the internal standard versus the expected calibrator 
concentration, using linear regression with a 1/x weighting over the range of 2.00–250. 
ng/mL (n = 24). Analyte detection was confirmed using a confirmation ion ratio, which is 
the ratio of the quantitation ion area to the confirmation ion area.
2.10 Safety considerations
The analysis of BChE and OPNA adducts to BChE posed no greater risk to analysts than 
general peptide analyses. Universal safety precautions were followed when handling 
biological specimens such as blood products.
3. Results and discussion
3.1 UHPLC-MS/MS optimization
The MS/MS fragmentation spectra for BChE and MeP-BChE have been previously reported.
(Carter et al., 2013, Fidder et al., 2002, Knaack et al., 2012, Sporty et al., 2010) When 
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adducted BChE peptides (FGESAGAAS) are fragmented using collision-induced 
dissociation, β-elimination of the OPNA adduct is observed, converting the adducted serine 
into a dehydroalanine (m/z 778.3) (Figure 4). For the MeP-BChE, EtP-BChE, PrP-BChE, 
and P-BChE peptides, quantitation was based on the transition of each respective [M+H]+ 
precursor ion to the product ion m/z 778.3. Confirmation of the MeP-BChE, EtP-BChE, 
PrP-BChE, and P-BChE peptides was based on the transition of each respective [M+H]+ 
precursor ion to the product ion m/z 673.3, which results from the loss of the OPNA adduct 
and further fragmentation to the b8 ion. Due to ion intensities, ExP-BChE quantitation was 
based on the transition from the precursor ion [M+H]+ m/z 904.3 to the product ion m/z 
673.3 and confirmed by the transition from the precursor ion [M+H]+ m/z 904.3 to the 
product ion m/z 778.3. In-source fragmentation was not observed for the OPNA-BChE or 
unadducted BChE peptides. The MS/MS transitions used for the native and labeled peptides 
can be found in Table 1.
The Restek Pinnacle DB Biphenyl (1.9 μm, 2.1 × 50 mm) analytical column was chosen for 
chromatographic separation, using a gradient of increasing mobile phase B as follows: 5–
23% (1.55 min), 23–76% B (0.28 min), 76% B (0.17 min), 5% B (1.00 min). The retention 
time for calibrators and QCs are provided in Table 2. Time-segmented multiple reaction 
monitoring mode gave at least 15 data points across each peak at the lowest reportable limit 
(LRL) and also allowed for optimization of dwell time for each segment. An extracted ion 
chromatogram displaying all biomarker peptides is presented in Figure 5. P-BChE and MeP-
BChE transitions were acquired in time-segment 1 (0.00–1.54 min) with a 35 ms dwell time. 
ExP-BChE and EtP-BChE transitions were acquired in time-segment 2 (1.54–1.65 min) with 
a 20 ms dwell time. BChE and PrP-BChE transitions were acquired in time-segment 3 
(1.65–1.90 min) with a 35 ms dwell time. See Table 1 for parameters for peptide detection.
3.2 Accuracy and Precision
To assess accuracy, precision, linearity, and limits of detection, data from 24 processed 
analytical runs (calibration curve and QCs) were evaluated. LC-MS/MS data was collected 
over four weeks, processing no more than two analytical runs per day. Calibration curves 
were linear for all analytes with a coefficient of determination value R2 ≥ 0.980 over the 
range of 2.00–250. ng/mL. The slope and y-intercept of the calibration curve were 
determined by linear least squares regression with 1/x weighting using the MassHunter 
Quantitative Analysis software package. Table 2 lists the interday accuracy and precision for 
each analyte at the lowest and highest calibrator levels, as well as the limit of detection 
(LOD) values that were calculated using the Taylor method.(Taylor, 1987) The lowest 
calibrator for each analyte was used as the lowest reportable limit. Determination of the 
method’s accuracy and precision followed the guidelines in the FDA’s guidance for 
bioanalytical method validation and thus show applicability for the analysis of clinical 
samples.(FDA, 2001) All analytes at all calibration levels demonstrated precision within 
15 %RSD, with the exception of the 2.00 ng/mL calibrator for EtP-BChE which had a 
calculated %RSD of 24. All analytes were observed within 15 %RE, with the exception of 
the 2.00 ng/mL calibrator for BChE and PrP-BChE which had calculated %RE values of 18 
and 25, respectively.
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Calculated concentrations of all QC materials from interday and intraday analysis were 
found to be within 15 %RSD with the exception of QL-P-BChE, which had an interday 
%RSD of 22 (Table 3). The serum used for QL-P-BChE was inhibited with CBDP, which 
undergoes hydrolysis to form P-BChE.(Schopfer et al., 2010) Previously reported methods 
were used to confirm that the CBDP-inhibited serum was not fully aged.(Johnson et al., 
2015) Therefore, the level of P-BChE in this material was expected to increase with time 
resulting in a greater %RSD. The imprecision observed in this QC is a reflection of adduct 
stability in the material and not the assay. Future editions of this assay will require more 
stable P-BChE QC materials.
3.3 Recovery and Matrix Effects
Since an isotopically-labeled BChE protein is not commercially available, extraction 
efficiency of aged OPNA-BChE and unadducted BChE peptides was assessed by adding 
calibrators (2.00, 32.0, and 250. ng/mL) to matrix blank serum either before (“processed”) 
or after (“unprocessed”) pepsin digestion. The processed samples were representative of the 
sample preparation used for synthetic peptide calibrators in this method. The average peak 
areas (n = 4) from these samples were used to evaluate recovery. The mean percentage 
recoveries for all analytes were ≥ 76% at all concentrations evaluated (Table 4). Potential 
losses in recovery may be attributed to nonspecific pepsin digestion and peptide adsorption 
to plastic surfaces.
Matrix effects were assessed by comparing the average peak area of unprocessed calibrators 
that were added to matrix blank serum after pepsin digestion and calibrators that were 
spiked into 0.6% formic acid in water. This was carried out with low, mid, and high 
calibrators. Matrix effects ranged from 5–17% for aged adducts and accounted for an 
approximate 35% reduction in mean peak area for unadducted BChE.
3.4 Stability and ruggedness
All calibrators and QC materials were found to have concentrations within the acceptable 
characterized values that were determined by the MRQCS for up to 8 freeze-thaw cycles. All 
calibrators were found to be stable up to 72 hours at 4 °C, room temperature, and 37 °C. 
QM-BChE was found to be stable up to 7 days at 4 °C, room temperature, and 37 °C, with 
the BChE concentration at each temperature/time point within the acceptable characterized 
QC range.
Method ruggedness was evaluated for all analytes using five parameters that represent steps 
in the UHPLC-MS/MS analysis that might be impacted by changes to the validated assay. 
The resuspension buffer of peptides prior to UHPLC-MS/MS analysis was evaluated with 
0.6% and 0.1% formic acid in water and no differences were observed. The LC organic 
mobile phase was evaluated by using either acetonitrile or methanol, each containing 0.1% 
formic acid. While both organic mobile phases produced QC results within ± 2 standard 
deviations of their characterized means, signal intensity was significantly higher (i.e. > 50%) 
with acetonitrile. The use of a linear gradient did not alter method performance, but 
increasing the gradient slope did impact calculated QC concentrations. When gradient slope 
was increased (5–35% B, 35–85% B), 13.3% (2 of 15) of QCs were outside of ± 2 standard 
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deviations of their characterized means. Changes to the LC flow rate were evaluated at 200 
μL/min and 400 μL/min. The decreased flow rate impacted the assay with 20% of QCs 
falling outside of their characterized values, most likely due to insufficient equilibration of 
the chromatograph. The increased flow rate had some impact on assay accuracy with 6.7% 
of QCs falling outside of their characterized concentration. The use of LC columns from 
multiple product lots showed potential to significantly impact the assay due to shifts in 
retention time. Of the eight product lots evaluated, three produced results in which at least 
one analyte’s retention time was shifted by more than 10%. This method uses segmented 
MRM to maximize dwell time, and significant shifts in retention time can prevent MS/MS 
analysis if the peak elutes outside of its analysis segment. When time segments were 
removed and dwell times were reduced to account for increased cycle time, the assay 
produced accurate quantitation, but chromatographic peak areas were reduced which could 
lead to decreased sensitivity.
3.5 Matrix blank serum and convenience set analysis
The matrix blank material used in this method consisted of unadducted pooled human serum 
filtered through a 10 kDa molecular weight cutoff filter. This is different from other methods 
developed in this laboratory which have used GB-inhibited serum or GA-inhibited serum as 
a matrix blank.(Carter et al., 2013, Johnson et al., 2015, Pantazides et al., 2014) These 
inhibited matrices could not be selected for this method since GB inhibited BChE ages to 
MeP-BChE and GA inhibited BChE can age to form P-BChE or ExP-BChE. All three of 
these aged products are measured in this assay so use of GA or GB inhibited serum would 
interfere with the detection of aged biomarkers as the materials aged. A comparison of 
matrix blank sera was conducted, and it was determined that slopes of calibration curves in 
unaged GB-inhibited, unaged GA-inhibited, and 10 kDa filtered serum differed by less than 
5%; therefore, 10 kDa filtered serum was determined to be an acceptable alternative matrix 
blank. Calibrators were also processed in 0.6% formic acid water, but calibration curve 
slopes differed by more than 5% when compared to GA and GB inhibited serum so 0.6% 
formic acid in water was not used as a matrix blank.
To assess background and possible interferences, a commercially-purchased convenience set 
of 96 individual human serum samples with no expected nerve agent exposure was analyzed. 
The average BChE nonapeptide concentration in human serum was found to be 40.0 ± 9.8 
ng/mL with a range of 18.4 – 61.7 ng/mL, which was in agreement with results previously 
reported.(Pantazides et al., 2014) A BChE nonapeptide concentration of 40.0 ng/mL in 
serum is representative of a BChE enzyme concentration of 50 nM which is consistent with 
previously reported concentrations of BChE in human serum.(Lockridge, 2015, Noort et al., 
2002, Tacal and Lockridge, 2010) Only the unadducted BChE biomarker was found to be 
present in the convenience set; no aged OPNA-BChE adducts were detected.
3.6 Evaluation of nerve agent spiked materials
Following an OPNA exposure event, blood samples undergo aging whether in vivo or ex 
vivo. This clinical assay provides an expansion of laboratory capabilities, allowing for the 
detection of all prohibited Schedule 1 OPNAs. This assay can also play an important role in 
the detection of OPNA exposure for patients who have received oxime therapy. The aged 
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adduct would be the only BChE biomarker expected to remain following oxime therapy 
since unaged adducts would be lost during BChE reactivation.(Berry and Davies, 1966)
OPNAs are known to age at different rates depending on the composition of the o-alkyl 
group; therefore, the ability to measure aged adducts becomes increasingly important.(Berry 
and Davies, 1966) Previously developed methods were used to study the thermal stability of 
sarin in serum and plasma.(Carter et al., 2013, Pantazides et al., 2014) When GB inhibited 
serum and plasma matrices were stored at 22 °C and 37 °C, the decay half-life of GB-BChE 
(-•-) was monitored respective to the storage temperature and matrix (Figure 6). The plot of 
GB-BChE decay in serum at 37 °C is shown in Figure 6, where the linear fit is y = 0.0226x 
+ 3.5972, R2=0.9578. The calculated half-lives (Table 5) of decay at 22 °C are similar (<1 % 
difference) intra-matrix, but in serum, the biomarker GB-BChE had a 15 % longer half-life 
than in plasma. At 37 °C, an expected decrease in biomarker half-life was observed for GB-
BChE. The measurable change in biomarker growth or decay did not exceed one half-life for 
sarin inhibited serum and plasma matrices stored at 4 °C.
According to previous reports on biomarker formation, the authors assumed first order 
conditions in the calculation of this work’s rate constants.(Aurbek et al., 2009, Davies and 
Green, 1956, Ellman et al., 1961, Evans et al., 2008) In doing so, the ex vivo change in 
biomarker stability at 37 °C in GB inhibited serum and plasma was calculated (Table 6). For 
each analyte, an assumed first order rate constant (k) was reported. The decay for GB-BChE 
was 0.02 h−1 in both serum and plasma. The formation of MeP-BChE from GB-BChE was 
0.05 h−1 in serum and 0.03 h−1 in plasma. The formation of unadducted BChE from GB-
BChE was 0.03 h−1 in serum and 0.01 h−1 in plasma. Activation parameters for GB-BChE 
were calculated from the temperature dependence of the rate constants in GB inhibited 
serum and plasma assuming first order conditions (Table 6). The activation energy of GB-
BChE was calculated to be 14 kcal/mol in serum and 9.7 kcal/mol in plasma. The pre-
exponential factor for GB-BChE was found to be 7.1 × 107 h−1 in serum and 1.3 × 105 h−1 
in plasma.
Since hydrolysis of GB-BChE leads to the formation of MeP-BChE and unadducted BChE, 
each biomarker was monitored in an example ex vivo study of sarin inhibited pooled serum 
stored at 37 °C (Scheme 2). At t=0 of the study, 100% of the BChE target monitored was 
observed as the GB-BChE biomarker at 41 ng/mL. After 861 hours (36 days), the MeP-
BChE remained the most abundant biomarker (22 ng/mL, 54%), and unadducted BChE was 
still present (8.3 ng/mL, 20%). The GB-BChE biomarker, however, was no longer detected. 
Since the MeP-BChE and unadducted BChE biomarkers only accounted for 74% of the 
initial GB-BChE concentration, an untargeted analysis was used to search for a singular 
unknown decay product. A number of masses were identified, but they neither accounted for 
only one decay product of GB-BChE nor possessed the signature MS/MS fragmentation 
expected of the adducted BChE biomarkers.
Additional agents were evaluated for their respective aged adducts to BChE in spiked serum. 
As anticipated, GE aged to form EtP-BChE, which was measured to be 40.6 ± 5.3 ng/mL in 
the GE-spiked serum. GV aged to form P-BChE and was determined to be 29.8 ± 3.4 ng/mL 
in the GV-spiked serum. Serum inhibited with Pr-GB aged to form PrP-BChE with a 
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measured concentration of 15.1 ± 0.7 ng/mL. All nerve agent-spiked serum samples had a 
BChE inhibition of at least 98% so changes in aged biomarker concentrations are likely the 
result of differences in the rates of aging. Of note, synthetic peptide standards for GE-, GV-, 
and Pr-GB-BChE were not available at the time of this work to measure their unaged BChE 
adduct concentrations.
4. Conclusions
A quantitative method was developed for the confirmation of exposure to OPNAs in clinical 
samples through detection of aged OPNA-BChE adducts. The method allows for the 
detection of all CWC Schedule 1 OPNAs by monitoring their resulting aged OPNA-BChE 
biomarkers P-BChE, MeP-BChE, ExP-BChE, EtP-BChE, and PrP-BChE, as well as 
unadducted BChE. In the analysis of a commercial convenience set of 96 individual serum 
samples, no aged OPNA-BChE adducts were observed and quantitative measurements of 
unadducted BChE were in agreement with previous studies using similar methodologies. 
This method allows for the quantitation of unadducted BChE and the aged OPNA-BChE 
biomarkers over a concentration range of 2.00 to 250. ng/mL and has demonstrated high 
intraday and interday accuracy and precision of calibration standards and spiked QC 
materials. The analysis of pooled uninhibited serum QC materials demonstrated high assay 
precision and is in agreement with FDA guidance for bioanalytical methods. The various 
aged OPNA-BChE biomarkers provide valuable information by confirming OPNA exposure 
over a prolonged period of time.
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Figure 1. 
Schedule 1 OPNAs inhibit BChE at Ser-198 and age to form MeP-BChE, EtP-BChE, PrP-
BChE, ExP-BChE, or P-BChE. The CWC defines Schedule 1 OPNAs as (A) o-alkyl (C ≤ 
10) alkyl (methyl, ethyl, n-propyl, or i-propyl)-phosphonofluoridates (ex. GB, GD, GE, GF, 
Pr-GB); (B) o-alkyl (C ≤ 10) N,N-dialkyl (methyl, ethyl, n-propyl, or i-propyl)-
phosphoramidocyanidates (ex. GA); (C) o-alkyl (H or C ≤ 10) S-2-dialkyl (methyl, ethyl, n-
propyl, or i-propyl)-aminoethyl alkyl (methyl, ethyl, n-propyl, or i-propyl) 
phosphonothiolates (ex. VE, VM, VR, VX).(OPCW, 2005)
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Figure 2. 
Chemical structures of the isotopically-labeled (A) unadducted BChE peptide 
(FGESAGAAS), (B) P-BChE (R = H) and ExP-BChE (R = C2H5), and (C) MeP-BChE (R = 
CH3), EtP-BChE (R = C2H5), and PrP-BChE (R = C3H7). An asterisk (*) indicates sites 
of 13C-isotope labeling.
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Figure 3. 
Chemical structures of the organophosphorus nerve agents (A) GE (ethyl sarin), (B) GV (2-
dialkylaminoalkyl N,N-dialkylphosphonamidofluoridate), (C) Pr-GB (propyl-sarin), (D) VE 
(O-ethyl-S-diethylaminoethylphosonothiolate).
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Figure 4. 
Chemical structure and product ion mass spectrum of the precursor ion for the synthetic 
peptide (A) EtP-BChE ([M+H]+ m/z 888.3), (B) ExP-BChE ([M+H]+ m/z 904.3), (C) P-
BChE ([M+H]+ m/z 876.3), and (D) PrP-BChE ([M+H]+ m/z 902.4). Fragmentation spectra 
were collected by scanning the mass range m/z 500–1000, using a collision energy of (A) 
35V, (B) 34V, (C) 32V, (D) 35V. The dashed lines indicate the proposed sites of 
fragmentation. The peptide sequence shown is FGESAGAAS.
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Figure 5. 
Overlay of extracted ion chromatograms of synthetic peptides for unadducted BChE and 
aged OPNA-BChE biomarkers. The black-filled peaks are aged OPNA-BChE peptides (P-
BChE, MeP-BChE, EtP-BChE, and PrP-BChE), the black outline with no fill is the aged 
ExP-BChE peptide, and the black outline with gray fill is the unadducted BChE peptide.
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Figure 6. 
The biomarker GB-BChE was evaluated ex vivo at 22 °C and 37 °C from GB inhibited 
serum ( ) and plasma ( ). (A) The decay of GB-BChE in serum and plasma is 
shown at 37 °C, where y = −0.0226x + 3.60, R2 = 0.958 and y = −0.0195x + 3.40, R2 = 
0.909, respectively and (B) the temperature dependence of kobs is plotted where y = 9391x 
− 26.6, R2 = 0.951 and y = 8652x − 24.2, R2 = 0.990.
Graham et al. Page 22
Biomed Chromatogr. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Scheme 1. 
Flowchart summarizing sample preparation.
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Scheme 2. 
Upon hydrolysis of the GB-BChE ( ) biomarker, MeP-BChE ( ) and BChE ( ) form via 
aging and regeneration.
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Table 4
Average recovery of calibrators in matrix blank serum added before (“processed”) or after (“unprocessed”) 
pepsin digestion. (n = 4)
Analyte Calibrator(ng/mL) Processed(mean area ± SD) Unprocessed(mean area ± SD) % Recoverya± SDb
P-BChE
2.00 (4.12 ± 0.75) × 102 (4.81 ± 0.72) × 102 86 ± 2
32.0 (5.71 ± 0.32) × 103 (7.16 ± 0.52) × 103 76 ± 1
250. (4.89 ± 0.31) × 104 (6.41 ± 0.35) × 104 76 ± 1
MeP-BChE
2.00 (9.85 ± 1.23) × 102 (1.10 ± 0.07) × 103 89 ± 1
32.0 (1.36 ± 0.05) × 104 (1.78 ± 0.11) × 104 76 ± 1
250. (1.23 ± 0.10) × 105 (1.60 ± 0.59) × 105 77 ± 1
ExP-BChE
2.00 (8.67 ± 1.30) × 102 (1.02 ± 0.10) × 103 85 ± 1
32.0 (1.40 ± 0.05) × 104 (1.77 ± 0.08) × 104 79 ± 1
250. (1.24 ± 0.10) × 105 (1.63 ± 0.06) × 105 76 ± 1
EtP-BChE
2.00 (1.30 ± 0.24) × 103 (1.55 ± 0.25) × 103 84 ± 3
32.0 (1.03 ± 0.13) × 104 (1.40 ± 0.20) × 104 73 ± 1
250. (9.90 ± 1.08) × 104 (1.28 ± 0.14) × 105 77 ± 1
BChE
2.00 (4.99 ± 0.64) × 102 (5.75 ± 0.60) × 102 87 ± 1
32.0 (8.78 ± 0.51) × 103 (1.11 ± 0.10) × 104 79 ± 1
250. (7.66 ± 0.78) × 104 (1.01 ± 0.07) × 105 76 ± 1
PrP-BChE
2.00 (1.53 ± 0.18) × 103 (1.72 ± 0.21) × 103 89 ± 1
32.0 (3.87 ± 0.18) × 104 (4.92 ± 0.28) × 104 79 ± 1
250. (3.57 ± 0.39) × 105 (4.59 ± 0.36) × 105 78 ± 1
a% Recovery = [(meanproc)/(meanun) × 100
bSD(% Recovery) = % Recovery × [(σun/meanun)2 + (σproc/meanproc)2]1/2
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Table 5
GB-BChE half-lives were calculated in serum and plasma at 22 °C and 37 °C.
t1/2 (h)* 22 °C 37 °C
Serum 93 (20%) 31 (10%)
Plasma 79 (20%) 36 (10%)
*
RSD
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